Allogene Therapeutics Inc (ALLO)
2.96
+0.04
(+1.54%)
USD |
NASDAQ |
May 02, 16:00
2.96
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Cash from Financing (TTM): 95.70M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 95.70M |
September 30, 2023 | 95.59M |
June 30, 2023 | 92.37M |
March 31, 2023 | 2.867M |
December 31, 2022 | 2.95M |
September 30, 2022 | 3.226M |
June 30, 2022 | 4.543M |
March 31, 2022 | 7.733M |
December 31, 2021 | 11.96M |
September 30, 2021 | 24.62M |
June 30, 2021 | 26.09M |
Date | Value |
---|---|
March 31, 2021 | 623.05M |
December 31, 2020 | 633.59M |
September 30, 2020 | 677.09M |
June 30, 2020 | 674.80M |
March 31, 2020 | 74.86M |
December 31, 2019 | 58.96M |
September 30, 2019 | 347.01M |
June 30, 2019 | 619.50M |
March 31, 2019 | 771.87M |
December 31, 2018 | 771.18M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.867M
Minimum
Mar 2023
677.09M
Maximum
Sep 2020
214.55M
Average
74.86M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
Agenus Inc | 119.87M |
ANI Pharmaceuticals Inc | 67.44M |
Vaxart Inc | 15.24M |
aTyr Pharma Inc | 66.23M |
PAVmed Inc | 31.17M |